A clinical evaluation of patients with known mutations (plasminogen and factor XII) with a focus on prophylactic treatment

References

• Sharma J, Jindal AK, Banday AZ, et al. Pathophysiology of hereditary angioedema (HAE) beyond the SERPING1 gene. Clin Rev Allergy Immunol. 2021;60(3):1–7. doi: 10.1007/s12016-021-08835-8.
   PubMed Web of Science ®Google Scholar
• Grumach AS, Veronez CL, Csuka D, et al. Angioedema without wheals: challenges in laboratorial diagnosis. Front Immunol. 2021;12:785736. doi: 10.3389/fimmu.2021.785736.
   PubMed Web of Science ®Google Scholar
• Santacroce R, D’Andrea G, Maffione AB, et al. The genetics of hereditary angioedema: a review. J Clin Med. 2021;10(9):2023. doi: 10.3390/jcm10092023.
   PubMed Web of Science ®Google Scholar
• Lepelley M, Bernardeau C, Defendi F, et al. Update on bradykinin-mediated angioedema in 2020. Therapies. 2020;75(2):195–205. doi: 10.1016/j.therap.2020.02.011.
   PubMed Web of Science ®Google Scholar
• Bernstein JA. HAE update: epidemiology and burden of disease. Allergy Asthma Proc. 2013;34(1):3–6. doi: 10.2500/aap.2013.34.3623.
   PubMed Web of Science ®Google Scholar
• Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—the 2021 revision and update. Allergy. 2022;77(7):1961–1990. doi: 10.1111/all.15214.
   PubMed Web of Science ®Google Scholar
• Riedl MA. Hereditary angioedema with normal C1-INH (HAE type III). J Allergy Clin Immunol Pract. 2013;1(5):427–432. doi: 10.1016/j.jaip.2013.06.004.
   PubMed Web of Science ®Google Scholar
• Christiansen SC, Zuraw BL. Laboratory approaches for assessing contact system activation. Immunol Allergy Clin North Am. 2017;37(3):527–539. doi: 10.1016/j.iac.2017.04.008.
   PubMed Web of Science ®Google Scholar
• Bork K, Machnig T, Wulff K, et al. Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence. Orphanet J Rare Dis. 2020;15(1):289. doi: 10.1186/s13023-020-01570-x.
   PubMed Web of Science ®Google Scholar
• Bork K, Gül D, Hardt J, et al. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am J Med. 2007;120(11):987–992. doi: 10.1016/j.amjmed.2007.08.021.
   PubMed Web of Science ®Google Scholar
• Bork K, Barnstedt SE, Koch P, et al. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet. 2000;356(9225):213–217. doi: 10.1016/S0140-6736(00)02483-1.
   PubMed Web of Science ®Google Scholar
• Magerl M, Germenis AE, Maas C, et al. Hereditary angioedema with normal C1 inhibitor. Immunol Allergy Clin North Am. 2017;37(3):571–584. doi: 10.1016/j.iac.2017.04.004.
   PubMed Web of Science ®Google Scholar
• Bork K. Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor; 2010 [cited 2023 June]. Available from: http://www.aacijournal.com/content/6/1/15 doi: 10.1186/1710-1492-6-15.
   Google Scholar
• Bork K, Wulff K, Witzke G, et al. Hereditary angioedema with normal C1-INH with versus without specific F12 gene mutations. Allergy. 2015;70(8):1004–1012. doi: 10.1111/all.12648.
   PubMed Web of Science ®Google Scholar
• Shamanaev A, Dickeson SK, Ivanov I, et al. Mechanisms involved in hereditary angioedema with normal C1-inhibitor activity. Front Physiol. 2023;14:1146834. doi: 10.3389/fphys.2023.1146834.
   PubMed Web of Science ®Google Scholar
• Bork K, Wulff K, Witzke G, et al. Treatment of patients with hereditary angioedema with the c.988A > G (p.Lys330Glu) variant in the plasminogen gene. Orphanet J Rare Dis. 2020;15(1):52. doi: 10.1186/s13023-020-1334-8.
   PubMed Web of Science ®Google Scholar
• Jones DH, Bansal P, Bernstein JA, et al. Clinical profile and treatment outcomes in patients with hereditary angioedema with normal C1 esterase inhibitor. World Allergy Organ J. 2022;15(1):100621. doi: 10.1016/j.waojou.2021.100621.
   PubMed Web of Science ®Google Scholar
• Weller K, Groffik A, Magerl M, et al. Development and construct validation of the angioedema quality of life questionnaire. Allergy. 2012;67(10):1289–1298. doi: 10.1111/all.12007.
   PubMed Web of Science ®Google Scholar
• Weller K, Donoso T, Magerl M, et al. Development of the angioedema control test-a patient-reported outcome measure that assesses disease control in patients with recurrent angioedema. Allergy. 2020;75(5):1165–1177. doi: 10.1111/all.14144.
   PubMed Web of Science ®Google Scholar
• Binkley KE, Davis A 3rd. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol. 2000;106(3):546–550. doi: 10.1067/mai.2000.108106.
   Google Scholar
• Riedl MA, Danese M, Danese S, et al. Hereditary angioedema with normal C1 inhibitor: US survey of prevalence and provider practice patterns. J Allergy Clin Immunol Pract. 2023;11(8):2450.e6–2456.e6. doi: 10.1016/j.jaip.2023.01.023.
   Web of Science ®Google Scholar
• Hahn J, Hoess A, Friedrich DT, et al. Unnecessary abdominal interventions in patients with hereditary angioedema. J Dtsch Dermatol Ges. 2018;16(12):1443–1449. doi: 10.1111/ddg.13698.
   Web of Science ®Google Scholar
• Bouillet L, Boccon-Gibod I, Gompel A, et al. Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (berinert®) in a french cohort. Eur J Dermatol. 2017;27(2):155–159. doi: 10.1684/ejd.2016.2948.
   PubMed Web of Science ®Google Scholar
• Deroux A, Boccon-Gibod I, Fain O, et al. Hereditary angioedema with normal C1 inhibitor and factor XII mutation: a series of 57 patients from the french national center of reference for angioedema. Clin Exp Immunol. 2016;185(3):332–337. doi: 10.1111/cei.12820.
   PubMed Web of Science ®Google Scholar
• Hintze S, Möhl BS, Beyerl J, et al. Mutant plasminogen in hereditary angioedema is bypassing FXII/kallikrein to generate bradykinin. Front Physiol. 2022;13:1090732. doi: 10.3389/fphys.2022.1090732.
   PubMed Web of Science ®Google Scholar
• Watt M, Malmenäs M, Romanus D, et al. Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema. J Comp Eff Res. 2023;12(6):e220188. doi: 10.57264/cer-2022-0188.
   PubMed Web of Science ®Google Scholar
• Bouillet L, Bocquet A, Belbezier A, et al. Effectiveness of lanadelumab in patients with hereditary angioedema with normal C1 inhibitor and FXII mutation. Ann Allergy Asthma Immunol. 2021;127(3):391–392. doi: 10.1016/j.anai.2021.05.028.
   PubMed Web of Science ®Google Scholar